Browse the evidence

Progressive weight loss exceeding 30% induces 100% remission of hyperinsulinemia (HI) and insulin resistance (IR) in individuals with overweight or obesity, whereas lower weight loss thresholds yield partial or no remission.

If you have high insulin or insulin resistance, losing a small amount of weight (5-10%) will help your health, but it likely won't cure the metabolic issue. To fully reverse hyperinsulinemia and insulin resistance, you generally need to lose more than 30% of your body weight through a sustained, intensive lifestyle and medical program over a year.

Time-restricted eating (TRE) significantly reduces body weight and fasting insulin levels in overweight and obese women compared to control groups, without negatively affecting fat-free or lean body mass.

If you are overweight or obese, try restricting your eating window to 8-10 hours a day (e.g., 10 AM to 6 PM). This approach has been shown to help women lose weight and improve insulin sensitivity without losing muscle mass, and it is often easier to stick to than strict calorie counting.

Lactobacillus sp. probiotic supplementation significantly reduces body mass index, body weight, waist and hip circumference, and visceral/subcutaneous fat mass in non-comorbid obese individuals compared to placebo.

If you are obese without other major health conditions, adding a Lactobacillus probiotic (doses ranging from 1 million to 50 billion CFU daily) to your routine may help reduce body weight, BMI, and waist circumference. The effect is modest but statistically significant, particularly when taken for at least 12 weeks. It is not a magic bullet but may support other lifestyle changes.

Resistance training combined with high protein intake (1.6-2.0 g/kg/day) preserves or increases muscle mass during caloric restriction, whereas high protein intake alone is insufficient without resistance training.

To lose fat without losing muscle, you must lift weights (at least 10 sets per muscle group per week) and eat 1.6-2.0 grams of protein per kilogram of body weight daily. Do not rely on protein shakes or dieting alone.

In adults with obesity without diabetes, tirzepatide produces significantly greater weight loss and cardiometabolic improvements than semaglutide over 6 months, even when semaglutide patients receive higher maintenance doses.

If you are choosing between tirzepatide and semaglutide for obesity management without diabetes, tirzepatide offers greater weight loss and better cardiometabolic improvements over 6 months. This advantage holds true even if you are on a higher maintenance dose of semaglutide than the typical tirzepatide dose. Consult your doctor to determine which medication aligns best with your health profile and insurance coverage.

Higher adherence to the VLCKD program, measured by number of medical visits and total doses consumed, is positively associated with greater success in weight loss, BMI reduction, and fat mass loss.

Attend all scheduled medical and nutritional visits. The study shows that higher adherence, measured by attending visits and consuming the prescribed doses, is significantly associated with better weight loss and fat loss outcomes.

Six months of intermittent fasting (2-3 non-consecutive days of vegetable-only fasting per week) significantly reduces body weight, body fat, and improves lipid profiles (LDL-C, non-HDL-C, triglycerides) in middle-aged adults with overweight, without significantly affecting blood pressure, fasting glucose, or inflammatory markers.

If you are overweight and middle-aged, trying intermittent fasting 2-3 days a week with a vegetable-only diet on those days can significantly improve your weight and cholesterol levels without needing to change your diet on other days. This approach is well-tolerated and offers specific metabolic benefits beyond just eating less.

Time-restricted eating (TRE) significantly reduces body weight, fat mass, BMI, and waist circumference in adults, but does not significantly reduce fat mass percentage.

If you are an adult looking to lose weight and body fat, restricting your daily eating window to 12-20 hours (fasting for 4-12 hours) is an effective strategy. You can expect significant reductions in body weight, waist circumference, and fat mass. However, be aware that this method also leads to a loss of fat-free mass (muscle) and does not significantly change your body fat percentage. It is not necessarily superior to standard calorie restriction for weight loss, but may be easier to adhere to for some people.

Reducing total caloric intake by 500-1,000 kcal daily (Low-Calorie Diet) is a safe, practical, and effective primary strategy for obesity management, yielding 0.5-1.0 kg weight loss per week.

To lose weight safely, reduce your daily calories by 500 to 1,000 compared to what you normally eat. This simple deficit typically results in losing 0.5 to 1.0 kg per week and is considered safe for most people without strict medical supervision.

Combining flexible time-restricted eating (8-hour window) with aerobic exercise yields significantly greater fat mass reduction than either intervention alone in middle-aged women with overweight/obesity.

If you are a middle-aged woman with overweight or obesity, combining an 8-hour eating window with regular moderate aerobic exercise (like brisk walking or jogging) will result in significantly more fat loss than doing either one alone. You do not need to count calories or stick to fixed meal times; simply choose an 8-hour window each day that fits your schedule and stay active.

Flexible time-restricted eating combined with aerobic exercise improves insulin resistance (HOMA-IR) and insulin levels more effectively than either intervention alone.

To improve your insulin sensitivity, combining an 8-hour eating window with regular moderate aerobic exercise is more effective than doing either one alone. This approach helps lower insulin levels and improve insulin resistance markers more significantly than diet or exercise in isolation.

A plant-based caloric restriction diet (PB-CRD) using a '5+2' structured meal plan is non-inferior to conventional calorie-restricted diets (CRD) for weight loss in obese adults, while providing superior reductions in total body fat percentage and improvements in metabolic markers including insulin sensitivity, uric acid, and liver enzymes.

To lose weight and improve metabolic health, you can follow a structured plant-based diet that restricts calories to 1,300-1,600 kcal/day. You do not need to be vegan 7 days a week; eating standardized plant-based meals for 5 days and allowing flexible, calorie-controlled meals for 2 days is effective. This approach matches the weight loss of traditional calorie restriction but offers better improvements in body fat percentage, insulin sensitivity, and liver health.

Intermittent fasting (16:8 time-restricted eating) produces significantly greater weight loss and improvements in fasting glucose and triglycerides compared to standard calorie restriction in obese adults over an 8-week period.

If you are obese and struggling with weight loss, try a 16:8 intermittent fasting schedule (eat within an 8-hour window, fast for 16) for at least 8 weeks. This approach may yield better weight loss and metabolic improvements than simply counting calories, and it is generally well-tolerated.

Daily consumption of 100 mg Kaempferia parviflora extract (SIRTMAX®) for 12 weeks significantly reduces body fat mass and visceral fat area in overweight adults compared to placebo.

Take 100 mg of Kaempferia parviflora extract (SIRTMAX®) once daily before breakfast for 12 weeks. This specific extract has been shown in a clinical trial to significantly reduce body fat mass and visceral fat in overweight adults, even without changing diet or exercise habits. It is not a magic bullet, but it provides a measurable advantage over placebo.

Semaglutide 2.4 mg weekly produces substantial and durable weight loss (10-15%) in adults with overweight or obesity through central appetite suppression, delayed gastric emptying, and improved glucose homeostasis.

If you have obesity, semaglutide 2.4 mg taken once weekly is a highly effective treatment for significant weight loss (10-15%). It works by reducing appetite and slowing digestion. Start with a low dose to minimize stomach upset, which usually improves over time. It is a long-term commitment, not a quick fix.

African American women with obesity and low insulin sensitivity lose significantly more fat mass and maintain higher total energy expenditure when following a low-carbohydrate diet compared to a low-fat diet.

If you are an African American woman with obesity and have struggled to lose weight on standard low-fat diets, switching to a low-carbohydrate approach (around 20% carbs, 55% fat) may help you lose more fat and keep your metabolism higher. This benefit is specifically linked to having lower insulin sensitivity, which is common in this demographic. Focus on whole foods, complex carbohydrates, and healthy fats while maintaining a caloric deficit.

Tirzepatide at 15 mg and maximum tolerated dose (MTD) provides superior weight loss efficacy compared to semaglutide (2.4 mg and MTD) in non-diabetic adults with obesity, but this benefit is offset by significantly higher rates of gastrointestinal side effects and treatment discontinuation.

If you are a non-diabetic adult with obesity seeking maximum weight loss, tirzepatide at 15mg or MTD is statistically more effective than semaglutide. However, you must accept a higher risk of gastrointestinal side effects and a higher chance of stopping the medication due to those side effects. Discuss your tolerance for potential side effects versus the desire for maximum weight loss with your provider.

Semaglutide significantly reduces Major Adverse Cardiovascular Events (MACE) and hospitalization for heart failure (HHF) risk, while Tirzepatide significantly reduces HHF risk, offering cardiovascular protection beyond weight loss.

If you have obesity and cardiovascular disease or heart failure, Semaglutide and Tirzepatide are not just weight loss drugs; they offer proven cardiovascular protection. Semaglutide reduces the risk of major heart events, and Tirzepatide reduces hospitalizations for heart failure. These benefits are independent of, but additive to, the weight loss achieved.

GIP has pleiotropic effects beyond glucose metabolism, including potential benefits for obesity, bone health, and neurodegenerative disorders, making it a candidate for pharmacotherapies.

GIP is not just a blood sugar hormone. It also influences fat storage, bone density, and brain health. This is why new drugs that mimic or modify GIP are being studied for obesity and even neurodegenerative diseases.

Contrave (naltrexone/bupropion) promotes weight loss (~6% TBWL) and may improve fertility by mitigating PCOS and endometriosis effects, though it is less effective than GLP-1 RAs.

Contrave is an oral option for weight loss that targets food cravings and reward pathways. It typically results in about 6% weight loss. It is less potent than GLP-1 injections but may help with emotional eating. You must stop taking it before trying to conceive.

GLP-1 receptor agonists (semaglutide) and dual GLP-1/GIP agonists (tirzepatide) cause significant lean mass loss during weight loss, with semaglutide losing approximately 45% of total weight as lean mass and tirzepatide losing 25.7%, posing a specific risk of frailty and fractures in older populations.

If you are taking semaglutide or tirzepatide, be aware that a significant portion of your weight loss (up to 45% for semaglutide) comes from lean mass, not just fat. This is especially risky if you are over 60. Discuss strategies to preserve muscle, such as resistance training or potentially newer combination therapies, with your provider.

GLP-1RAs reduce food intake and body weight by activating POMC neurons and inhibiting NPY/AgRP neurons in the arcuate nucleus (ARC) of the hypothalamus.

GLP-1 medications also work in the brain's 'hunger center' (arcuate nucleus) by boosting 'stop eating' signals (POMC) and reducing 'start eating' signals (NPY/AgRP). This dual action helps reduce overall food intake and body weight.

Discontinuation of anti-obesity medications (AOMs) leads to significant weight regain starting at 8 weeks post-treatment, with the trajectory stabilizing by 26 weeks.

If you stop taking anti-obesity medication, expect to regain weight starting around 2 months later. This is a biological response to the loss of the drug's appetite-suppressing effects, not a lack of willpower. Long-term management likely requires ongoing treatment or intensive lifestyle support to counteract this regain.

Adherence to the Mediterranean diet (MeDi) is associated with improved cognitive performance and a delay in cognitive decline in elderly populations, particularly when enriched with extra virgin olive oil or nuts.

Adopt a Mediterranean-style eating pattern focusing on extra virgin olive oil, vegetables, fruits, whole grains, and nuts. This approach is more effective for cognitive health than taking single supplements. Prioritize high-polyphenol olive oil and moderate wine intake if appropriate for your health profile.